Orexigen Therapeutics to Present at Upcoming Conferences
SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:
The 14th Annual BIO CEO & Investor Conference
Date: February 13, 2012
Time: 1:30pm Eastern Time
Location: Waldorf Astoria, New York
Speaker: Michael Narachi, President and Chief Executive Officer
Leerink Swann Global Healthcare Conference
Date: February 15, 2012
Time: 8:00am Eastern Time
Location: Waldorf Astoria, New York
Speaker: Michael Narachi, President and Chief Executive Officer
To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Corporate Contacts: Orexigen
Orexigen |
Media |
Jay Hagan |
Denise Powell |
Chief Business Officer |
WCG |
(858) 875-8673 |
(510) 703-9491 |
SOURCE Orexigen Therapeutics, Inc.
Share this article